Akt: A Therapeutic Target in Hepatic Ischemia–Reperfusion Injury

Journal of Investigative Surgery

Volumn 30, Issue 1, 2017, Pages 47-55

  Covington, Stephen M ^a   Bauler, Laura D ^b   Toledo Pereyra, Luis H ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b WESTERN MICHIGAN UNIVERSITY HOMER STRYKER MD SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; ischemia; post conditioning; pre conditioning; reperfusion; therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; MICRORNA; PROTEIN KINASE B; CARDIOTROPHIN 1; CYTOKINE; REACTIVE OXYGEN METABOLITE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CELL DAMAGE; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE THERAPY; HUMAN; INTRACELLULAR SIGNALING; ISCHEMIC PRECONDITIONING; LIVER CELL; LIVER GRAFT; LIVER HISTOLOGY; LIVER ISCHEMIA; MEDLINE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; REPERFUSION INJURY; REVIEW; SCOPUS; SYSTEMATIC REVIEW; ANIMAL; APOPTOSIS; BLOOD; DRUG EFFECT; GENE TRANSFER; GENETICS; LIVER; LIVER TRANSPLANTATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION; PRIMARY GRAFT DYSFUNCTION; PROCEDURES; SIGNAL TRANSDUCTION; VASCULARIZATION;

ALANINE TRANSAMINASE; ANIMALS; APOPTOSIS; CYTOKINES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; ISCHEMIC PRECONDITIONING; LIVER; LIVER TRANSPLANTATION; MICRORNAS; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PRIMARY GRAFT DYSFUNCTION; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84980015798     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.1080/08941939.2016.1206999     Document Type: Review

References (75)

1. Unos.org. Transplant trends. Online Data Base|United Network of Organ Sharing, 2015.
2. Mullonkal CJ, Toledo-Pereyra LH. Akt in ischemia and reperfusion. J Invest Surg. 2007;20(3):195–203.
3. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. +2005;9(1):59–71
4. Staal SP, Hartley JW, Rowe WP. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci USA 1977;74(7):3065–3067.
5. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991;254(5029):274–277
6. Grammer TC, Cheatham L, Chou MM, Blenis J. The p70(S6K) signalling pathway:A novel signalling system involved in growth regulation. Cancer Surv. 1996;27:271–292.
7. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997;275(5300):661–665.
8. Datta SR, Dudek H, Xu T, Masters S, Haian F, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell- intrinsic death machinery. Cell 1997;91(2):231–241.
9. Ouyang Y, Tan Y, Comb M, Liu C, Marione ME, Siesjö BK, et al. Survival- and death-promoting events after transient cerebral ischemia:Phosphorylation of Akt, release of cytochrome C, and activation of caspase—like proteases. J Cereb Blood Flow Metab. 1999;19(10):1126–1135.
10. Kitagawa H, Warita H, Sasaki C, Ri Zhang W, Sakai K, Shiro Y, et al. Immunoreactive Akt, PI3-K and ERK protein kinase expression in ischemic rat brain. Neurosci Lett. 1999;274(1):45–48.
11. Li J, Li R, Lv G, Liu H. The mechanisms and strategies to protect from hepatic ischemia–reperfusion injury. Eur Rev Med Pharmacol Sci. 2015;19(11):2036–2047.
12. Chang WJ, Chehab M, Kink S, Toledo-Pereyra LH. Intracellular calcium signaling pathways during liver ischemia and reperfusion. J Invest Surg. 2010;23(4):228–238.
13. Weigand K, Brost S, Steinebrunner N, Bchler M, Schemmer P, Müller M. Ischemia/Reperfusion injury in liver surgery and transplantation:Pathophysiology. HPB Surg. 2012;2012.
14. Teoh NC, Farrell GC. Hepatic ischemia reperfusion injury:Pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol. 2003;18(8):891–902.
15. Southard JH, Marshu DC, McAnulty JF, Belzer FO. Oxygen-derived free radical damage in organ preservation:Activity of superoxide dismutase and xanthine oxidase. Surgery (USA) 1987;101(5):566–570.
16. Peglow S, Toledo AH, Anaya-Prado R, Lopez-Neblina F, Toledo-Pereyra LH. Allopurinol and xanthine oxidase inhibition in liver ischemia reperfusion. J Hepato-Biliary-Pancreatic Sci. 2011;18(2):137–146.
17. Amacher DE. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol. 1998;27(2):119–130.
18. Sherman KE., Alanine Aminotransferase in Clinical Practice:A Review. Arch Intern Med. 1991;151(2):260–265.
19. Tang B, Qiao H, Meng F, Sun X. Glycyrrhizin attenuates endotoxin-induced acute liver injury after partial hepatectomy in rats. Braz J Med Biol Res. 2007;40(12):1637–1646.
20. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia:A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74(5):1124–1136.
21. Carini R, De Cesaris MG, Splendore R, Baldanzi G, Nitti MP, Alchera E, et al. Role of phosphatidylinositol 3-kinase in the development of hepatocyte preconditioning. Gastroenterology 2004;127(3):914–923.
22. Izuishi K, Tsung A, Hossain MA, Fujiwara M, Wakabayashi H, Masaki T, et al. Ischemic preconditioning of the murine liver protects through the Akt kinase pathway. Hepatology 2006;44(3):573–580.
23. Zhao Z, Corvera JS, Halkos ME, Kerendi F, Wang N, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion:Comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285(2 54-2):H579–H588.
24. Buckberg GD. Studies of controlled reperfusion after ischemia. I. When is cardiac muscle damaged irreversibly? J Thorac Cardiovasc Surg. 1986;92(3 II):483–487.
25. Schipke JD, Halkos ME, Kerendi F, Gams E, Vinten-Johansen J. Postconditioning:A brief review. Arch Med Sci. 2006;2(3):137–145.
26. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning:A form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res. 2004;95(3):230–232.
27. Guo JY, Yang T, Sun XG, Zhou NY, Li FS, Long D, et al. Ischemic postconditioning attenuates liver warm ischemia–reperfusion injury through Akt-eNOS-NO-HIF pathway. J Biomed Sci. 2011;18(1).
28. Zhu J, Lu T, Yue S, Shen X, Gao F, Busuttil RW, et al. Rapamycin protection of livers from ischemia and reperfusion injury is dependent on both autophagy induction and mammalian target of rapamycin complex 2-akt activation. Transplantation 2015;99(1):48–55.
29. Grossini E, Pollesello P, Bellofatto K, Sigaudo L, Farruggio S, Origlia V, et al. Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats. Liver Transplant 2014;20(3):361–375.
30. Guo Y, Yang T, Lu J, Li S, Wan L, Long D, et al. Rb1 postconditioning attenuates liver warm ischemia–reperfusion injury through ROS-NO-HIF pathway. Life Sci. 2011;88(13-14):598–605.
31. Gui B, Hua F, Chen J, Xu Z, Sun H, Qian Y. Protective effects of pretreatment with oleanolic acid in rats in the acute phase of hepatic ischemia–reperfusion injury:Role of the PI3K/Akt pathway. Mediators Inflamm. 2014;2014:1–7.
32. Bejaoui M, Zaouali MA, Folch-Puy E, Pantazi E, Bardag-Gorce F, Carbonell T, et al. Bortezomib enhances fatty liver preservation in Institut George Lopez-1 solution through adenosine monophosphate activated protein kinase and Akt/mTOR pathways. J Pharm Pharmacol.2014;66(1):62–72.
33. Aguilar-Melero P, Luque A, Machuca MM, Pérez De Obanos MP, Navarrete R, Rodríguez-García IC, et al. Cardiotrophin-1 reduces ischemia/reperfusion injury during liver transplant. J Surg Res. 2013;181(2):E83–E91.
34. Yang X, Qin L, Liu J, Tian L, Qian H. 17β-Estradiol protects the liver against cold ischemia/reperfusion injury through the Akt kinase pathway. J Surg Res. 2012;178(2):996–1002.
35. Zhang R, Zhang L, Manaenko A, Ye Z, Liu W, Sun X. Helium preconditioning protects mouse liver against ischemia and reperfusion injury through the PI3KPI3K/Akt pathway. J Hepatol. 2014;61:1048–1055.
36. Kim HJ, Joe Y, Kong JS, Jeong S-, Cho GJ, Ryter SW, et al. Carbon monoxide protects against hepatic ischemia/reperfusion injury via ROS-dependent akt signaling and inhibition of glycogen synthase kinase 3 β;. Oxidative Med Cell Longevity 2013;2013:1–11.
37. Nandra KK, Collino M, Rogazzo M, Fantozzi R, Patel NSA, Thiemermann C. Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock. DNM Dis Models Mech 2013;6(3):701–709.
38. Suo L, Kang K, Wang X, Cao Y, Zhao H, Sun X, et al. Carvacrol alleviates ischemia reperfusion injury by regulating the PI3K-Akt pathway in rats. PLoS ONE 2014;9(8):1–10.
39. Koh P., Melatonin prevents hepatic injury-induced decrease in Akt downstream targets phosphorylations. J Pineal Res. 2011;51(2):214–219.
40. Ohi N, Nishikawa Y, Tokairin T, Yamamoto Y, Doi Y, Omori Y, et al. Maintenance of bad phosphorylation prevents apoptosis of rat hepatic sinusoidal endothelial cells in vitro and in vivo. Am J Pathol. 2006;168(4):1097–1106.
41. Grutzner U, Keller M, Bach M, Kiemer AK, Meissner H, Bilzer M, et al. PI 3-kinase pathway is responsible for antiapoptotic effects of atrial natriuretic peptide in rat liver transplantation. World J Gastroenterol. 2006;12(7):1049–1055.
42. Sheng M, Zhou Y, Yu W, Weng Y, Xu R, Du H. Protective effect of berberine pretreatment in hepatic ischemia/reperfusion injury of rat. Transplant Proc. 2015;47(2):275–282.
43. Müller C, Dünschede F, Koch E, Vollmar AM, Kiemer AK. α-lipoic acid preconditioning reduces ischemia–reperfusion injury of the rat liver via the PI3-kinase/Akt pathway. Am J Physiol Gastrointest Liver Physiol. 2003;285(4 48-4):G769–G778.
44. Park J, Kang J, Lee S-. Activation of the cholinergic anti-inflammatory pathway by nicotine attenuates hepatic ischemia/reperfusion injury via heme oxygenase-1 induction. Eur J Pharmacol. 2013;707(1–3):61–70.
45. Fu W, Liao X, Ruan J, Li X, Chen L, Wang B, et al. Recombinant human erythropoietin preconditioning attenuates liver ischemia reperfusion injury through the phosphatidylinositol-3 kinase/AKT/endothelial nitric oxide synthase pathway. J Surg Res. 2013;183(2):876–884.
46. Zhang T, Shu H-, Chang L, Ye F, Xu K-, Huang W-. Resolvin D1 protects against hepatic ischemia/reperfusion injury in rats. Int Immunopharmacol. 2015;28(1):322–327.
47. Wang D, Ma Y, Li Z, Kang K, Sun X, Pan S, et al. The role of AKT1 and autophagy in the protective effect of hydrogen sulfide against hepatic ischemia/reperfusion injury in mice. Autophagy 2012;8(6):954–962.
48. Hori T, Gardner LB, Hata T, Chen F, Baine A-T, Uemoto S, et al. Pretreatment of liver grafts in vivo by γ-aminobutyric acid receptor regulation reduces cold ischemia/warm reperfusion injury in rat. Ann Transplant 2013;18(1):299–313
49. Eldar-Finkelman H. Glycogen synthase kinase 3:An emerging therapeutic target. Trends Mol Med. 2002;8(3):126–132.
50. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M. Inhibition of GSK3β by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 2008;117(21):2761–2768.
51. Fu H, Xu H, Chen H, Li Y, Li W, Zhu Q, et al. Inhibition of glycogen synthase kinase 3 ameliorates liver ischemia/reperfusion injury via an energy-dependent mitochondrial mechanism. J Hepatol. 2014;61(4):816–824.
52. Honda K, Tohyama T, Kotegawa H, Kojima Y, Kushihata F, Watanabe J, et al. Protective effect of Adeno-mediated human Bcl-xLgene transfer to the mouse liver in a partial Ischemia/Reperfusion model. J Surg Res. 2009;157(1):e107–e116.
53. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun. 2005;333(2):336–343.
54. Yoshidome H, Kato A, Edwards MJ, Lentsch AB. Interleukin-10 suppresses hepatic ischemia/reperfusion injury in mice:Implications of a central role for nuclear factor κB. Hepatology 1999;30(1):203–208.
55. Iwakiri Y, Kim MY. Nitric oxide in liver diseases. Trends Pharmacol Sci. 2015;36(8):524–536.
56. Shah V, Kamath PS. Nitric oxide in liver transplantation:Pathobiology and clinical implications. Liver Transplant 2003;9(1):1–11.
57. Laplante M, Sabatini DM. MTOR signaling in growth control and disease. Cell 2012;149(2):274–293.
58. Kang J, Cho H, Lee S. Melatonin inhibits mTOR-dependent autophagy during liver ischemia/reperfusion. Cell Physiol Biochem. 2014;33(1):23–36.
59. Kezic A, Becker JU, Thaiss F. The effect of mTOR-inhibition on NF-κB activity in kidney ischemia–reperfusion injury in mice. Transplant Proc. 2013;45(5):1708–1714.
60. Suzuki T, Yoshidome H, Kimura F, Shimizu H, Ohtsuka M, Takeuchi D, et al. Hepatocyte apoptosis is enhanced after ischemia/reperfusion in the steatotic liver. J Clin Biochem Nutr. 2011;48(2):142–148.
61. Johnson CR, Jarvis WD. Caspase-9 regulation:An update. Apoptosis 2004;9(4):423–427.
62. Tsalkidou EG, Tsaroucha AK, Chatzaki E, Lambropoulou M, Papachristou F, Trypsianis G, et al. The effects of apigenin on the expression of Fas/FasL apoptotic pathway in warm liver ischemia–reperfusion injury in rats. Bio Med Res Int 2014;2014:1–7.
63. Van Rooij E, Purcell AL, Levin AA. Developing MicroRNA therapeutics. Circ Res. 2012;110(3):496–507.
64. Shen G, Li X, Jia Y, Piazza GA, Xi Y. Hypoxia-regulated microRNAs in human cancer. Acta Pharmacol Sin. 2013;34(3):336–341.
65. Morita T, Ishikawa M, Sakamoto A. Identical microRNAs regulate liver protection during anaesthetic and ischemic preconditioning in rats:An animal study. PLoS ONE 2015;10(5).
66. Sun G, Zhou Y, Li H, Guo Y, Shan J, Xia M, et al. Over-expression of microRNA-494 up-regulates hypoxia-inducible factor-1 alpha expression via PI3K/Akt pathway and protects against hypoxia-induced apoptosis. J Biomed Sci. 2013;20(1).
67. Sayed D, He M, Hong C, Gao S, Rane S, Yang Z, et al. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of fas ligand. J Biol Chem. 2010;285(26):20281–20290.
68. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989–2004–An overview. J Gene Med. 2004;6(6):597–602.
69. Song J, Zhang Y, Yao A, Yu Y, Hua Z-, Pu L-, et al. Adenoviral cardiotrophin-1 transfer improves survival and early graft function after ischemia and reperfusion in rat small-for-size liver transplantation model. Transplant Int. 2008;21(4):372–383
70. Jia W, Li H, He Y. The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment. Blood 2005;106(12):3854–3859.
71. Sun P, Zhang P, Wang P-, Zhu L-, Du Y, Tian S, et al. Mindin deficiency protects the liver against ischemia/reperfusion injury. J Hepatol. 2015;63(5):1198–1211.
72. Hai T, Wolford CC, Chang Y-. ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases:Is modulation of inflammation a unifying component? Gene Expr. 2010;15(1):1–11.
73. Rao J, Qian X, Li G, Pan X, Zhang C, Zhang F, et al. ATF3-mediated NRF2/HO-1 signaling regulates TLR4 innate immune responses in mouse liver ischemia/reperfusion injury. Am J Transplant. 2015;15(1):76–87.
74. Bataille AM, Manautou JE. Nrf2 a potential target for new therapeutics in liver disease. Clin Pharmacol Ther. 2012;92(3):340–348.
75. Huang J, Yue S, Ke B, Zhu J, Shen X, Zhai Y, et al. Nuclear factor erythroid 2-related factor 2 regulates toll-like receptor 4 innate responses in mouse liver ischemia–reperfusion injury through Akt-forkhead box protein O1 signaling network. Transplantation 2014;98(7):721–728.